靶向 B7-H3-CAR-T 细胞中的 Regnase-1 重编程肿瘤微环境并增强骨肉瘤抗肿瘤疗效
Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.
肿瘤细胞治疗研究
FRONTIER PAPERS
近 5 年肿瘤细胞治疗领域的研究论文。默认按评分排序(权威性 + 新鲜度)。
Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.
Emerging Treatments in Bone Tumors: Lessons Learned from the ESMO Annual Meeting.
LRRC15-CAR T Cells for the Treatment of Osteosarcoma.
LRRC15-CAR-T 细胞在保持良好安全性特征的同时发挥抗骨肉瘤活性。
Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma.
基于人配体的 OSM CAR-T 细胞对多种骨肉瘤细胞系和患者样本显示出抗肿瘤效果。这些效果在体外、异种移植模型以及模拟转移性疾病的模型中得到了证实。总体而言,这些数据支持继续研究 OSM-CAR-T 细胞作为骨肉瘤新治疗途径。
Targeting Regnase-1 unleashes CAR T cell antitumor activity for osteosarcoma and creates a proinflammatory tumor microenvironment.
MEMBER ACCOUNT
登录成功会直接打开下一页。